Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power of...

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments Company Selects Refractory Advanced Genitourinary Malignancies including Renal Cell Cancer as Second Indication MILAN, Italy and NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Genenta Science...

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma MILAN, Italy and NEW YORK, June 29, 2023 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of...